ASND - Ascendis Pharma A/S

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

Currency in EUR. All numbers in thousands
Total Revenue10,5811,5304,6068,118
Cost of Revenue----
Gross Profit10,5811,5304,6068,118
Operating Expenses
Research Development140,28199,58966,02240,528
Selling General and Administrative25,05713,48211,5049,415
Non Recurring----
Total Operating Expenses165,338113,07177,52649,943
Operating Income or Loss-154,757-111,541-72,920-41,825
Income from Continuing Operations
Total Other Income/Expenses Net24,266-12,8334,1888,251
Earnings Before Interest and Taxes-154,757-111,541-72,920-41,825
Interest Expense-127-97-5-6
Income Before Tax-130,491-124,374-68,732-33,574
Income Tax Expense-394-477-227-652
Minority Interest----
Net Income From Continuing Ops-130,097-123,897-68,505-32,922
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-130,097-123,897-68,505-32,922
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-130,097-123,897-68,505-32,922